CoChat
Sign Up
Cited by 530Long-Term Effects of COVID-19COVID-19 Clinical Research StudiesInfectious Encephalopathies and Encephalitis

The DOI matches its Crossref record; 52 of the 54 references it cites were found in a registry or an index.

Long-term neurologic outcomes of COVID-19

Open access
Xu, Evan, Xie, Yan, Al-Aly, Ziyad·2022·Nature Medicine
DOI 10.1038/s41591-022-02001-zPMC PMC9671811

Published version of a preprint

Open this paper in CoChat — free accountOpen PDF

Abstract

The neurologic manifestations of acute COVID-19 are well characterized, but a comprehensive evaluation of postacute neurologic sequelae at 1 year has not been undertaken. Here we use the national healthcare databases of the US Department of Veterans Affairs to build a cohort of 154,068 individuals with COVID-19, 5,638,795 contemporary controls and 5,859,621 historical controls; we use inverse probability weighting to balance the cohorts, and estimate risks and burdens of incident neurologic disorders at 12 months following acute SARS-CoV-2 infection. Our results show that in the postacute phase of COVID-19, there was increased risk of an array of incident neurologic sequelae including ischemic and hemorrhagic stroke, cognition and memory disorders, peripheral nervous system disorders, episodic disorders (for example, migraine and seizures), extrapyramidal and movement disorders, mental health disorders, musculoskeletal disorders, sensory disorders, Guillain–Barré syndrome, and encephalitis or encephalopathy. We estimated that the hazard ratio of any neurologic sequela was 1.42 (95% confidence intervals 1.38, 1.47) and burden 70.69 (95% confidence intervals 63.54, 78.01) per 1,000 persons at 12 months. The risks and burdens were elevated even in people who did not require hospitalization during acute COVID-19. Limitations include a cohort comprising mostly White males. Taken together, our results provide evidence of increased risk of long-term neurologic disorders in people who had COVID-19.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-022-02001-z

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Cohort construction flowchart. Cohort construction for COVID-19 group (blue), contemporary control group (orange) and historical control group (pink). Comparisons between groups are presented in green.
Fig. 1 Cohort construction flowchart. Cohort construction for COVID-19 group (blue), contemporary control group (orange) and historical control group (pink). Comparisons between groups are presented in green.CC BY · PubMed Central
Fig. 2 Risks and 12-month burdens of incident postacute COVID-19 neurologic outcomes compared with the contemporary control cohort. Outcomes were ascertained 30 days after the COVID-19-positive test until the end of follow up. COVID-19 cohort (n = 154,068) and contemporary control cohort (n = 5,638,795). Adjusted HRs (dots) and 95% (error bars) CIs are presented, as are estimated excess burdens (bars) and 95% CIs (error bars). Burdens are presented per 1,000 persons at 12 months of follow up. The dashed line marks a HR of 1.00; lower limits of 95% CIs with values greater than 1.00 indicate significantly increased risk.
Fig. 2 Risks and 12-month burdens of incident postacute COVID-19 neurologic outcomes compared with the contemporary control cohort. Outcomes were ascertained 30 days after the COVID-19-positive test until the end of follow up. COVID-19 cohort (n = 154,068) and contemporary control cohort (n = 5,638,795). Adjusted HRs (dots) and 95% (error bars) CIs are presented, as are estimated excess burdens (bars) and 95% CIs (error bars). Burdens are presented per 1,000 persons at 12 months of follow up. The dashed line marks a HR of 1.00; lower limits of 95% CIs with values greater than 1.00 indicate significantly increased risk.CC BY · PubMed Central
Fig. 3 Risks and 12-month burdens of incident postacute COVID-19 composite neurologic outcomes compared with the contemporary control cohort. Composite outcomes consisted of cerebrovascular disorders (ischemic stroke, TIA, hemorrhagic stroke and cerebral venous thrombosis), cognition and memory (memory problems and Alzheimer’s disease), disorders of the peripheral nerves (peripheral neuropathy, paresthesia, dysautonomia and Bell’s palsy), episodic disorders (migraine, epilepsy and seizures and headache disorders), extrapyramidal and movement disorders (abnormal involuntary movements, tremor, Parkinson-like disease, dystonia, myoclonus), mental health disorders (major depressive disorders, stress and adjustment disorders, anxiety disorders, and psychotic disorders), musculoskeletal disorders (joint pain, myalgia and myopathy), sensory disorders (hearing abnormalities or tinnitus, vision abnormalities, loss of smell and loss of taste), other neurologic or related disorders (dizziness, somnolence, Guillain–Barré syndrome, encephalitis or encephalopathy and transverse myelitis) and any neurologic outcome (incident occurrence of any neurologic outcome studied). Outcomes were ascertained 30 days after the COVID-19-positive test until the end of follow up. The COVID-19 cohort had n = 154,068 and the contemporary control cohort had n = 5,638,795. Adjusted HRs (dots) and 95% (error bars) CIs are presented, as are estimated excess burdens (bars) and 95% CIs (error bars). Burdens are presented per 1,000 persons at 12 months of follow up. The dashed line marks a HR of 1.00; lower limits of 95% CIs with values greater than 1.00 indicate significantly increased risk.
Fig. 3 Risks and 12-month burdens of incident postacute COVID-19 composite neurologic outcomes compared with the contemporary control cohort. Composite outcomes consisted of cerebrovascular disorders (ischemic stroke, TIA, hemorrhagic stroke and cerebral venous thrombosis), cognition and memory (memory problems and Alzheimer’s disease), disorders of the peripheral nerves (peripheral neuropathy, paresthesia, dysautonomia and Bell’s palsy), episodic disorders (migraine, epilepsy and seizures and headache disorders), extrapyramidal and movement disorders (abnormal involuntary movements, tremor, Parkinson-like disease, dystonia, myoclonus), mental health disorders (major depressive disorders, stress and adjustment disorders, anxiety disorders, and psychotic disorders), musculoskeletal disorders (joint pain, myalgia and myopathy), sensory disorders (hearing abnormalities or tinnitus, vision abnormalities, loss of smell and loss of taste), other neurologic or related disorders (dizziness, somnolence, Guillain–Barré syndrome, encephalitis or encephalopathy and transverse myelitis) and any neurologic outcome (incident occurrence of any neurologic outcome studied). Outcomes were ascertained 30 days after the COVID-19-positive test until the end of follow up. The COVID-19 cohort had n = 154,068 and the contemporary control cohort had n = 5,638,795. Adjusted HRs (dots) and 95% (error bars) CIs are presented, as are estimated excess burdens (bars) and 95% CIs (error bars). Burdens are presented per 1,000 persons at 12 months of follow up. The dashed line marks a HR of 1.00; lower limits of 95% CIs with values greater than 1.00 indicate significantly increased risk.CC BY · PubMed Central
Fig. 4 Subgroup analyses of the risks of incident postacute COVID-19 composite neurologic outcomes compared with the contemporary control cohort. Composite outcomes consisted of cerebrovascular disorders (ischemic stroke, TIA, hemorrhagic stroke and cerebral venous thrombosis), cognition and memory (memory problems and Alzheimer’s disease) disorders, disorders of the peripheral nerves (peripheral neuropathy, paresthesia, dysautonomia and Bell’s palsy), episodic disorders (migraine, epilepsy and seizures, and headache disorders), extrapyramidal and movement disorders (abnormal involuntary movements, tremor, Parkinson-like disease, dystonia, myoclonus), mental health disorders (major depressive disorders, stress and adjustment disorders, anxiety disorders, and psychotic disorders), musculoskeletal disorders (joint pain, myalgia and myopathy), sensory disorders (hearing abnormalities or tinnitus, vision abnormalities, loss of smell and loss of taste), other neurologic or related disorders (dizziness, somnolence, Guillain–Barré syndrome, encephalitis or encephalopathy and transverse myelitis) and any neurologic outcome (incident occurrence of any neurologic outcome studied). Outcomes were ascertained 30 days after the COVID-19-positive test until the end of follow up. COVID-19 cohort (n = 154,068) and contemporary control cohort (n = 5,638,795). Adjusted HRs (dots) and 95% (error bars) CIs are presented. The dashed line marks a HR of 1.00; lower limits of 95% CIs with values greater than 1.00 indicate significantly increased risk.
Fig. 4 Subgroup analyses of the risks of incident postacute COVID-19 composite neurologic outcomes compared with the contemporary control cohort. Composite outcomes consisted of cerebrovascular disorders (ischemic stroke, TIA, hemorrhagic stroke and cerebral venous thrombosis), cognition and memory (memory problems and Alzheimer’s disease) disorders, disorders of the peripheral nerves (peripheral neuropathy, paresthesia, dysautonomia and Bell’s palsy), episodic disorders (migraine, epilepsy and seizures, and headache disorders), extrapyramidal and movement disorders (abnormal involuntary movements, tremor, Parkinson-like disease, dystonia, myoclonus), mental health disorders (major depressive disorders, stress and adjustment disorders, anxiety disorders, and psychotic disorders), musculoskeletal disorders (joint pain, myalgia and myopathy), sensory disorders (hearing abnormalities or tinnitus, vision abnormalities, loss of smell and loss of taste), other neurologic or related disorders (dizziness, somnolence, Guillain–Barré syndrome, encephalitis or encephalopathy and transverse myelitis) and any neurologic outcome (incident occurrence of any neurologic outcome studied). Outcomes were ascertained 30 days after the COVID-19-positive test until the end of follow up. COVID-19 cohort (n = 154,068) and contemporary control cohort (n = 5,638,795). Adjusted HRs (dots) and 95% (error bars) CIs are presented. The dashed line marks a HR of 1.00; lower limits of 95% CIs with values greater than 1.00 indicate significantly increased risk.CC BY · PubMed Central
Fig. 5 Risks and 12-month burdens of incident postacute COVID-19 neurologic outcomes compared with the contemporary control cohort by care setting of the acute infection. Risks and burdens were assessed at 12 months in mutually exclusive groups comprising nonhospitalized individuals with COVID-19 (green), individuals hospitalized for COVID-19 (orange) and individuals admitted to intensive care for COVID-19 during the acute phase (first 30 days) of COVID-19 (purple). Outcomes were ascertained 30 days after the COVID-19-positive test until the end of follow up. The contemporary control cohort served as the referent category. Within the COVID-19 cohort, nonhospitalized (n = 131,915), hospitalized (n = 16,764), admitted to intensive care (n = 5,389) and contemporary control cohort (n = 5,606,761). Adjusted HRs (dots) and 95% (error bars) CIs are presented, as are estimated excess burdens (bars) and 95% CIs (error bars). Burdens are presented per 1,000 persons at 12 months of follow up. ICU, intensive care unit. The dashed line marks a HR of 1.00; lower limits of 95% CIs with values greater than 1.00 indicate significantly increased risk.
Fig. 5 Risks and 12-month burdens of incident postacute COVID-19 neurologic outcomes compared with the contemporary control cohort by care setting of the acute infection. Risks and burdens were assessed at 12 months in mutually exclusive groups comprising nonhospitalized individuals with COVID-19 (green), individuals hospitalized for COVID-19 (orange) and individuals admitted to intensive care for COVID-19 during the acute phase (first 30 days) of COVID-19 (purple). Outcomes were ascertained 30 days after the COVID-19-positive test until the end of follow up. The contemporary control cohort served as the referent category. Within the COVID-19 cohort, nonhospitalized (n = 131,915), hospitalized (n = 16,764), admitted to intensive care (n = 5,389) and contemporary control cohort (n = 5,606,761). Adjusted HRs (dots) and 95% (error bars) CIs are presented, as are estimated excess burdens (bars) and 95% CIs (error bars). Burdens are presented per 1,000 persons at 12 months of follow up. ICU, intensive care unit. The dashed line marks a HR of 1.00; lower limits of 95% CIs with values greater than 1.00 indicate significantly increased risk.CC BY · PubMed Central
Fig. 6 Risks and 12-month burdens of incident postacute COVID-19 composite neurologic outcomes compared with the contemporary control cohort by care setting of the acute infection. Risks and burdens were assessed at 12 months in mutually exclusive groups comprising nonhospitalized individuals with COVID-19 (green), individuals hospitalized for COVID-19 (orange) and individuals admitted to intensive care for COVID-19 during the acute phase (first 30 days) of COVID-19 (purple). Composite outcomes consisted of cerebrovascular disorders (ischemic stroke, TIA, hemorrhagic stroke and cerebral venous thrombosis), cognition and memory disorders (memory problems and Alzheimer’s disease), disorders of the peripheral nerves (peripheral neuropathy, paresthesia, dysautonomia and Bell’s palsy), episodic disorders (migraine, epilepsy and seizures, and headache disorders), extrapyramidal and movement disorders (abnormal involuntary movements, tremor, Parkinson-like disease, dystonia, myoclonus), mental health disorders (major depressive disorders, stress and adjustment disorders, anxiety disorders, and psychotic disorders), musculoskeletal disorders (joint pain, myalgia and myopathy), sensory disorders (hearing abnormalities or tinnitus, vision abnormalities, loss of smell and loss of taste), other neurologic or related disorders (dizziness, somnolence, Guillain–Barré syndrome, encephalitis or encephalopathy and transverse myelitis) and any neurologic outcome (incident occurrence of any neurologic outcome studied). Outcomes were ascertained 30 days after the COVID-19-positive test until the end of follow up. The contemporary control cohort served as the referent category. Within the COVID-19 cohort were the nonhospitalized (n = 131,915), hospitalized (n = 16,764), those admitted to intensive care (n = 5,389) and contemporary control cohort (n = 5,606,761). Adjusted HRs (dots) and 95% (error bars) CIs are presented, as are estimated excess burdens (bars) and 95% CIs (error bars). Burdens are presented per 1,000 persons at 12 months of follow up. The dashed line marks a HR of 1.00; lower limits of 95% CIs with values greater than 1.00 indicate significantly increased risk.
Fig. 6 Risks and 12-month burdens of incident postacute COVID-19 composite neurologic outcomes compared with the contemporary control cohort by care setting of the acute infection. Risks and burdens were assessed at 12 months in mutually exclusive groups comprising nonhospitalized individuals with COVID-19 (green), individuals hospitalized for COVID-19 (orange) and individuals admitted to intensive care for COVID-19 during the acute phase (first 30 days) of COVID-19 (purple). Composite outcomes consisted of cerebrovascular disorders (ischemic stroke, TIA, hemorrhagic stroke and cerebral venous thrombosis), cognition and memory disorders (memory problems and Alzheimer’s disease), disorders of the peripheral nerves (peripheral neuropathy, paresthesia, dysautonomia and Bell’s palsy), episodic disorders (migraine, epilepsy and seizures, and headache disorders), extrapyramidal and movement disorders (abnormal involuntary movements, tremor, Parkinson-like disease, dystonia, myoclonus), mental health disorders (major depressive disorders, stress and adjustment disorders, anxiety disorders, and psychotic disorders), musculoskeletal disorders (joint pain, myalgia and myopathy), sensory disorders (hearing abnormalities or tinnitus, vision abnormalities, loss of smell and loss of taste), other neurologic or related disorders (dizziness, somnolence, Guillain–Barré syndrome, encephalitis or encephalopathy and transverse myelitis) and any neurologic outcome (incident occurrence of any neurologic outcome studied). Outcomes were ascertained 30 days after the COVID-19-positive test until the end of follow up. The contemporary control cohort served as the referent category. Within the COVID-19 cohort were the nonhospitalized (n = 131,915), hospitalized (n = 16,764), those admitted to intensive care (n = 5,389) and contemporary control cohort (n = 5,606,761). Adjusted HRs (dots) and 95% (error bars) CIs are presented, as are estimated excess burdens (bars) and 95% CIs (error bars). Burdens are presented per 1,000 persons at 12 months of follow up. The dashed line marks a HR of 1.00; lower limits of 95% CIs with values greater than 1.00 indicate significantly increased risk.CC BY · PubMed Central
Extended Data Fig. 1 Standardized mean difference of predefined and algorithmically selected high-dimensional variables. Standardized mean difference between COVID-19 and contemporary control.
Extended Data Fig. 1 Standardized mean difference of predefined and algorithmically selected high-dimensional variables. Standardized mean difference between COVID-19 and contemporary control.CC BY · PubMed Central
Extended Data Fig. 2 The risks of incident postacute COVID-19 composite neurologic outcomes across age compared with the contemporary control cohort. Composite outcomes consisted of cerebrovascular disorders (ischemic stroke, TIA, hemorrhagic stroke, and cerebral venous thrombosis), cognition and memory (memory problems and Alzheimer’s disease), disorders of the peripheral nerves (peripheral neuropathy, paresthesia, dysautonomia, and Bell’s palsy), episodic disorders (migraine, epilepsy and seizures, and headache disorders), extrapyramidal and movement disorders (abnormal involuntary movements, tremor, Parkinson-like disease, dystonia, myoclonus), mental health disorders (major depressive disorders, stress and adjustment disorders, anxiety disorders, and psychotic disorders), musculoskeletal disorders (joint pain, myalgia, and myopathy), sensory disorders (Hearing abnormalities or tinnitus, vision abnormalities, loss of smell, and loss of taste), other neurologic or related disorders (dizziness, somnolence, Guillain-Barré syndrome, encephalitis or encephalopathy and transverse myelitis), and any neurologic outcome (incident occurrence of any neurologic outcome studied). Outcomes were ascertained 30d after the COVID-19-positive test until the end of follow up. COVID-19 cohort (n = 154,068) and contemporary control cohort (n = 5,638,795). Age was transformed into restricted cubic spline function for the analyses. P value was based on 2-sided Wald Chi-Squared test on interaction between age and exposure, without multiple comparisons adjustment. A P value of <0.05 suggests that age modifies the association between COVID-19 and the neurologic outcome. The P value for cerebrovascular disorders=0.38, cognition and memory disorders=0.001, disorders of the peripheral nerves=0.15, episodic disorders<0.001, extrapyramidal and movement disorders=0.88, mental health disorders<0.001, musculoskeletal disorders<0.001, sensory disorders<0.001, other neurologic or related disorders<0.001, and any neurologic disorder=0.003.
Extended Data Fig. 2 The risks of incident postacute COVID-19 composite neurologic outcomes across age compared with the contemporary control cohort. Composite outcomes consisted of cerebrovascular disorders (ischemic stroke, TIA, hemorrhagic stroke, and cerebral venous thrombosis), cognition and memory (memory problems and Alzheimer’s disease), disorders of the peripheral nerves (peripheral neuropathy, paresthesia, dysautonomia, and Bell’s palsy), episodic disorders (migraine, epilepsy and seizures, and headache disorders), extrapyramidal and movement disorders (abnormal involuntary movements, tremor, Parkinson-like disease, dystonia, myoclonus), mental health disorders (major depressive disorders, stress and adjustment disorders, anxiety disorders, and psychotic disorders), musculoskeletal disorders (joint pain, myalgia, and myopathy), sensory disorders (Hearing abnormalities or tinnitus, vision abnormalities, loss of smell, and loss of taste), other neurologic or related disorders (dizziness, somnolence, Guillain-Barré syndrome, encephalitis or encephalopathy and transverse myelitis), and any neurologic outcome (incident occurrence of any neurologic outcome studied). Outcomes were ascertained 30d after the COVID-19-positive test until the end of follow up. COVID-19 cohort (n = 154,068) and contemporary control cohort (n = 5,638,795). Age was transformed into restricted cubic spline function for the analyses. P value was based on 2-sided Wald Chi-Squared test on interaction between age and exposure, without multiple comparisons adjustment. A P value of <0.05 suggests that age modifies the association between COVID-19 and the neurologic outcome. The P value for cerebrovascular disorders=0.38, cognition and memory disorders=0.001, disorders of the peripheral nerves=0.15, episodic disorders<0.001, extrapyramidal and movement disorders=0.88, mental health disorders<0.001, musculoskeletal disorders<0.001, sensory disorders<0.001, other neurologic or related disorders<0.001, and any neurologic disorder=0.003.CC BY · PubMed Central
Extended Data Fig. 3 Standardized mean difference of predefined and algorithmically selected high-dimensional variables. (a) by care setting of the acute infection between COVID-19 and contemporary control; (b) between COVID-19 and historical control; (c) by care setting of the acute infection between COVID-19 and historical control.
Extended Data Fig. 3 Standardized mean difference of predefined and algorithmically selected high-dimensional variables. (a) by care setting of the acute infection between COVID-19 and contemporary control; (b) between COVID-19 and historical control; (c) by care setting of the acute infection between COVID-19 and historical control.CC BY · PubMed Central
Extended Data Fig. 4 Risks and 12-month burdens of incident postacute COVID-19 neurologic outcomes compared with the historical control cohort. Outcomes were ascertained 30 d after the COVID-19-positive test until the end of follow-up. COVID-19 cohort (n = 154,068) and historical control cohort (n = 5,859,621). Adjusted HRs (dots) and 95% (error bars) CIs are presented, as are estimated excess burdens (bars) and 95% confidence intervals (error bars). Burdens are presented per 1000 persons at 12 months of follow up. The dashed line marks a HR of 1.00; lower limits of 95% CIs with values greater than 1.00 indicate significantly increased risk.
Extended Data Fig. 4 Risks and 12-month burdens of incident postacute COVID-19 neurologic outcomes compared with the historical control cohort. Outcomes were ascertained 30 d after the COVID-19-positive test until the end of follow-up. COVID-19 cohort (n = 154,068) and historical control cohort (n = 5,859,621). Adjusted HRs (dots) and 95% (error bars) CIs are presented, as are estimated excess burdens (bars) and 95% confidence intervals (error bars). Burdens are presented per 1000 persons at 12 months of follow up. The dashed line marks a HR of 1.00; lower limits of 95% CIs with values greater than 1.00 indicate significantly increased risk.CC BY · PubMed Central
Extended Data Fig. 5 Risks and 12-month burdens of incident postacute COVID-19 composite neurologic outcomes compared with the historical control cohort. Composite outcomes consisted of cerebrovascular disorders (ischemic stroke, TIA, hemorrhagic stroke, and cerebral venous thrombosis), cognition and memory (memory problems and Alzheimer’s disease), disorders of the peripheral nerves (peripheral neuropathy, paresthesia, dysautonomia, and Bell’s palsy), episodic disorders (migraine, epilepsy and seizures, and headache disorders), extrapyramidal and movement disorders (abnormal involuntary movements, tremor, Parkinson-like disease, dystonia, myoclonus), mental health disorders (major depressive disorders, stress and adjustment disorders, anxiety disorders, and psychotic disorders), musculoskeletal disorders (joint pain, myalgia, and myopathy), sensory disorders (Hearing abnormalities or tinnitus, vision abnormalities, loss of smell, and loss of taste), other neurologic or related disorders (dizziness, somnolence, Guillain-Barré syndrome, encephalitis or encephalopathy and transverse myelitis), and any neurologic outcome (incident occurrence of any neurologic outcome studied). Outcomes were ascertained 30d after the COVID-19-positive test until the end of follow up. COVID-19 cohort (n = 154,068) and historical control cohort (n = 5,859,621). Adjusted HRs (dots) and 95% (error bars) CIs are presented, as are estimated excess burdens (bars) and 95% confidence intervals (error bars). Burdens are presented per 1000 persons at 12 months of follow up. The dashed line marks a HR of 1.00; lower limits of 95% CIs with values greater than 1.00 indicate significantly increased risk.
Extended Data Fig. 5 Risks and 12-month burdens of incident postacute COVID-19 composite neurologic outcomes compared with the historical control cohort. Composite outcomes consisted of cerebrovascular disorders (ischemic stroke, TIA, hemorrhagic stroke, and cerebral venous thrombosis), cognition and memory (memory problems and Alzheimer’s disease), disorders of the peripheral nerves (peripheral neuropathy, paresthesia, dysautonomia, and Bell’s palsy), episodic disorders (migraine, epilepsy and seizures, and headache disorders), extrapyramidal and movement disorders (abnormal involuntary movements, tremor, Parkinson-like disease, dystonia, myoclonus), mental health disorders (major depressive disorders, stress and adjustment disorders, anxiety disorders, and psychotic disorders), musculoskeletal disorders (joint pain, myalgia, and myopathy), sensory disorders (Hearing abnormalities or tinnitus, vision abnormalities, loss of smell, and loss of taste), other neurologic or related disorders (dizziness, somnolence, Guillain-Barré syndrome, encephalitis or encephalopathy and transverse myelitis), and any neurologic outcome (incident occurrence of any neurologic outcome studied). Outcomes were ascertained 30d after the COVID-19-positive test until the end of follow up. COVID-19 cohort (n = 154,068) and historical control cohort (n = 5,859,621). Adjusted HRs (dots) and 95% (error bars) CIs are presented, as are estimated excess burdens (bars) and 95% confidence intervals (error bars). Burdens are presented per 1000 persons at 12 months of follow up. The dashed line marks a HR of 1.00; lower limits of 95% CIs with values greater than 1.00 indicate significantly increased risk.CC BY · PubMed Central
Extended Data Fig. 6 Subgroup analyses of the risks of incident postacute COVID-19 composite neurologic outcomes compared with the historical control cohort. Composite outcomes consisted of cerebrovascular disorders (ischemic stroke, TIA, hemorrhagic stroke, and cerebral venous thrombosis), cognition and memory (memory problems and Alzheimer’s disease), disorders of the peripheral nerves (peripheral neuropathy, paresthesia, dysautonomia, and Bell’s palsy), episodic disorders (migraine, epilepsy and seizures, and headache disorders), extrapyramidal and movement disorders (abnormal involuntary movements, tremor, Parkinson-like disease, dystonia, myoclonus), mental health disorders (major depressive disorders, stress and adjustment disorders, anxiety disorders, and psychotic disorders), musculoskeletal disorders (joint pain, myalgia, and myopathy), sensory disorders (Hearing abnormalities or tinnitus, vision abnormalities, loss of smell, and loss of taste), other neurologic or related disorders (dizziness, somnolence, Guillain-Barré syndrome, encephalitis or encephalopathy and transverse myelitis), and any neurologic outcome (incident occurrence of any neurologic outcome studied). Outcomes were ascertained 30d after the COVID-19-positive test until the end of follow up. COVID-19 cohort (n = 154,068) and historical control cohort (n = 5,859,621). Adjusted HRs (dots) and 95% (error bars) CIs are presented. The dashed line marks a HR of 1.00; lower limits of 95% CIs with values greater than 1.00 indicate significantly increased risk.
Extended Data Fig. 6 Subgroup analyses of the risks of incident postacute COVID-19 composite neurologic outcomes compared with the historical control cohort. Composite outcomes consisted of cerebrovascular disorders (ischemic stroke, TIA, hemorrhagic stroke, and cerebral venous thrombosis), cognition and memory (memory problems and Alzheimer’s disease), disorders of the peripheral nerves (peripheral neuropathy, paresthesia, dysautonomia, and Bell’s palsy), episodic disorders (migraine, epilepsy and seizures, and headache disorders), extrapyramidal and movement disorders (abnormal involuntary movements, tremor, Parkinson-like disease, dystonia, myoclonus), mental health disorders (major depressive disorders, stress and adjustment disorders, anxiety disorders, and psychotic disorders), musculoskeletal disorders (joint pain, myalgia, and myopathy), sensory disorders (Hearing abnormalities or tinnitus, vision abnormalities, loss of smell, and loss of taste), other neurologic or related disorders (dizziness, somnolence, Guillain-Barré syndrome, encephalitis or encephalopathy and transverse myelitis), and any neurologic outcome (incident occurrence of any neurologic outcome studied). Outcomes were ascertained 30d after the COVID-19-positive test until the end of follow up. COVID-19 cohort (n = 154,068) and historical control cohort (n = 5,859,621). Adjusted HRs (dots) and 95% (error bars) CIs are presented. The dashed line marks a HR of 1.00; lower limits of 95% CIs with values greater than 1.00 indicate significantly increased risk.CC BY · PubMed Central
Extended Data Fig. 7 The risks of incident postacute COVID-19 composite neurologic outcomes across age compared with the historical control cohort. Composite outcomes consisted of cerebrovascular disorders (ischemic stroke, TIA, hemorrhagic stroke, and cerebral venous thrombosis), cognition and memory (memory problems and Alzheimer’s disease), disorders of the peripheral nerves (peripheral neuropathy, paresthesia, dysautonomia, and bell’s palsy), episodic disorders (migraine, epilepsy and seizures, and headache disorders), extrapyramidal and movement disorders (abnormal involuntary movements, tremor, Parkinson-like disease, dystonia, myoclonus), mental health disorders (major depressive disorders, stress and adjustment disorders, anxiety disorders, and psychotic disorders), musculoskeletal disorders (joint pain, myalgia, and myopathy), sensory disorders (Hearing abnormalities or tinnitus, vision abnormalities, loss of smell, and loss of taste), other neurologic or related disorders (dizziness, somnolence, Guillain-Barré syndrome, encephalitis or encephalopathy and transverse myelitis), and any neurologic outcome (incident occurrence of any neurologic outcome studied). Outcomes were ascertained 30d after the COVID-19-positive test until the end of follow up. COVID-19 cohort (n = 154,068) and historical control cohort (n = 5,859,621). Age was transformed into restricted cubic spline function for the analyses. P value was based on 2 sided Wald Chi-Squared test on interaction between age and exposure, without multiple comparisons adjustment. A P value of <0.05 suggests that age modifies the association between COVID-19 and the neurologic outcome. The P value for cerebrovascular disorders=0.57, cognition and memory disorders=0.009, disorders of the peripheral nerves=0.04, episodic disorders<0.001, extrapyramidal and movement disorders=0.05, mental health disorders<0.001, musculoskeletal disorders<0.001, sensory disorders<0.001, other neurologic or related disorders=0.002, and any neurologic disorder<0.001.
Extended Data Fig. 7 The risks of incident postacute COVID-19 composite neurologic outcomes across age compared with the historical control cohort. Composite outcomes consisted of cerebrovascular disorders (ischemic stroke, TIA, hemorrhagic stroke, and cerebral venous thrombosis), cognition and memory (memory problems and Alzheimer’s disease), disorders of the peripheral nerves (peripheral neuropathy, paresthesia, dysautonomia, and bell’s palsy), episodic disorders (migraine, epilepsy and seizures, and headache disorders), extrapyramidal and movement disorders (abnormal involuntary movements, tremor, Parkinson-like disease, dystonia, myoclonus), mental health disorders (major depressive disorders, stress and adjustment disorders, anxiety disorders, and psychotic disorders), musculoskeletal disorders (joint pain, myalgia, and myopathy), sensory disorders (Hearing abnormalities or tinnitus, vision abnormalities, loss of smell, and loss of taste), other neurologic or related disorders (dizziness, somnolence, Guillain-Barré syndrome, encephalitis or encephalopathy and transverse myelitis), and any neurologic outcome (incident occurrence of any neurologic outcome studied). Outcomes were ascertained 30d after the COVID-19-positive test until the end of follow up. COVID-19 cohort (n = 154,068) and historical control cohort (n = 5,859,621). Age was transformed into restricted cubic spline function for the analyses. P value was based on 2 sided Wald Chi-Squared test on interaction between age and exposure, without multiple comparisons adjustment. A P value of <0.05 suggests that age modifies the association between COVID-19 and the neurologic outcome. The P value for cerebrovascular disorders=0.57, cognition and memory disorders=0.009, disorders of the peripheral nerves=0.04, episodic disorders<0.001, extrapyramidal and movement disorders=0.05, mental health disorders<0.001, musculoskeletal disorders<0.001, sensory disorders<0.001, other neurologic or related disorders=0.002, and any neurologic disorder<0.001.CC BY · PubMed Central
Extended Data Fig. 8 Risks and 12-month burdens of incident postacute COVID-19 neurologic outcomes by care setting of the acute infection compared with the historical control cohort. Risks and burdens were assessed at 12 months in mutually exclusive groups comprising nonhospitalized individuals with COVID-19 (green), individuals hospitalized for COVID-19 (orange) and individuals admitted to intensive care for COVID-19 during the acute phase (first 30 d) of COVID-19 (purple). Outcomes were ascertained 30 d after the COVID-19-positive test until the end of follow up. The historical control cohort served as the referent category. Within the COVID-19 cohort, nonhospitalized (n = 131,915), hospitalized (n = 16,764), admitted to intensive care (n = 5,389) and historical control cohort (n = 5,809,908). Adjusted HRs (dots) and 95% (error bars) CIs are presented, as are estimated excess burdens (bars) and 95% confidence intervals (error bars). Burdens are presented per 1000 persons at 12 months of follow up. The dashed line marks a HR of 1.00; lower limits of 95% CIs with values greater than 1.00 indicate significantly increased risk.
Extended Data Fig. 8 Risks and 12-month burdens of incident postacute COVID-19 neurologic outcomes by care setting of the acute infection compared with the historical control cohort. Risks and burdens were assessed at 12 months in mutually exclusive groups comprising nonhospitalized individuals with COVID-19 (green), individuals hospitalized for COVID-19 (orange) and individuals admitted to intensive care for COVID-19 during the acute phase (first 30 d) of COVID-19 (purple). Outcomes were ascertained 30 d after the COVID-19-positive test until the end of follow up. The historical control cohort served as the referent category. Within the COVID-19 cohort, nonhospitalized (n = 131,915), hospitalized (n = 16,764), admitted to intensive care (n = 5,389) and historical control cohort (n = 5,809,908). Adjusted HRs (dots) and 95% (error bars) CIs are presented, as are estimated excess burdens (bars) and 95% confidence intervals (error bars). Burdens are presented per 1000 persons at 12 months of follow up. The dashed line marks a HR of 1.00; lower limits of 95% CIs with values greater than 1.00 indicate significantly increased risk.CC BY · PubMed Central
Extended Data Fig. 9 Risks and 12-month burdens of incident postacute COVID-19 composite neurologic outcomes by care setting of the acute infection compared with the historical control cohort. Risks and burdens were assessed at 12 months in mutually exclusive groups comprising nonhospitalized individuals with COVID-19 (green), individuals hospitalized for COVID-19 (orange) and individuals admitted to intensive care for COVID-19 during the acute phase (first 30 d) of COVID-19 (purple). Composite outcomes consisted of cerebrovascular disorders (ischemic stroke, TIA, hemorrhagic stroke, and cerebral venous thrombosis), cognition and memory (memory problems and Alzheimer’s disease), disorders of the peripheral nerves (peripheral neuropathy, paresthesia, dysautonomia, and Bell’s palsy), episodic disorders (migraine, epilepsy and seizures, and headache disorders), extrapyramidal and movement disorders (abnormal involuntary movements, tremor, Parkinson-like disease, dystonia, myoclonus), mental health disorders (major depressive disorders, stress and adjustment disorders, anxiety disorders, and psychotic disorders), musculoskeletal disorders (joint pain, myalgia, and myopathy), sensory disorders (Hearing abnormalities or tinnitus, vision abnormalities, loss of smell, and loss of taste), other neurologic or related disorders (dizziness, somnolence, Guillain-Barré syndrome, encephalitis or encephalopathy and transverse myelitis), and any neurologic outcome (incident occurrence of any neurologic outcome studied). Outcomes were ascertained 30 d after the COVID-19-positive test until the end of follow up. The historical control cohort served as the referent category. Within the COVID-19 cohort, nonhospitalized (n = 131,915), hospitalized (n = 16,764), admitted to intensive care (n = 5,389) and historical control cohort (n = 5,809,908). Adjusted HRs (dots) and 95% (error bars) CIs are presented, as are estimated excess burdens (bars) and 95% confidence intervals (error bars). Burdens are presented per 1000 persons at 12 months of follow up. The dashed line marks a HR of 1.00; lower limits of 95% CIs with values greater than 1.00 indicate significantly increased risk.
Extended Data Fig. 9 Risks and 12-month burdens of incident postacute COVID-19 composite neurologic outcomes by care setting of the acute infection compared with the historical control cohort. Risks and burdens were assessed at 12 months in mutually exclusive groups comprising nonhospitalized individuals with COVID-19 (green), individuals hospitalized for COVID-19 (orange) and individuals admitted to intensive care for COVID-19 during the acute phase (first 30 d) of COVID-19 (purple). Composite outcomes consisted of cerebrovascular disorders (ischemic stroke, TIA, hemorrhagic stroke, and cerebral venous thrombosis), cognition and memory (memory problems and Alzheimer’s disease), disorders of the peripheral nerves (peripheral neuropathy, paresthesia, dysautonomia, and Bell’s palsy), episodic disorders (migraine, epilepsy and seizures, and headache disorders), extrapyramidal and movement disorders (abnormal involuntary movements, tremor, Parkinson-like disease, dystonia, myoclonus), mental health disorders (major depressive disorders, stress and adjustment disorders, anxiety disorders, and psychotic disorders), musculoskeletal disorders (joint pain, myalgia, and myopathy), sensory disorders (Hearing abnormalities or tinnitus, vision abnormalities, loss of smell, and loss of taste), other neurologic or related disorders (dizziness, somnolence, Guillain-Barré syndrome, encephalitis or encephalopathy and transverse myelitis), and any neurologic outcome (incident occurrence of any neurologic outcome studied). Outcomes were ascertained 30 d after the COVID-19-positive test until the end of follow up. The historical control cohort served as the referent category. Within the COVID-19 cohort, nonhospitalized (n = 131,915), hospitalized (n = 16,764), admitted to intensive care (n = 5,389) and historical control cohort (n = 5,809,908). Adjusted HRs (dots) and 95% (error bars) CIs are presented, as are estimated excess burdens (bars) and 95% confidence intervals (error bars). Burdens are presented per 1000 persons at 12 months of follow up. The dashed line marks a HR of 1.00; lower limits of 95% CIs with values greater than 1.00 indicate significantly increased risk.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 54 references

Research works printed but not linked: 2

  1. Xie, Y., Xu, E., Bowe, B. & Al-Aly, Z. Long-term cardiovascular outcomes of COVID-19. Nat. Med. 28, 583–590 (2022). · DOI
  2. Hernán, M. A. & Robins, J. M. Causal Inference: What If (Chapman & Hall/CRC, 2020).

Cited by

Sorted by citations

See all 530

Related

Metadata

Authors
Xu, E., Xie, Y., & Al-Aly, Z.
Affiliations
VA St. Louis Health Care System (US)
ORCID
Venue
Nature Medicine
Publisher
Springer Science and Business Media LLC
Published
2022-09-22
Volume
28
Issue
11
Pages
2406-2415
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
DOI
10.1038/s41591-022-02001-z
PMC
PMC9671811
OpenAlex
W4296806570
Cited by
530
References
54
Citations by year
2026: 61 · 2025: 107 · 2024: 168 · 2023: 166 · 2022: 27
FWCI
61.58
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
Funders
  • U.S. Department of Veterans Affairs
  • American Society of Nephrology
Topics
  • Health Sciences › Medicine › Clinical Neurology › Long-Term Effects of COVID-19
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Infectious Diseases › Infectious Encephalopathies and Encephalitis
Keywords
COVID-19 pandemic, SARS-CoV-2, long-term neurologic outcome, stroke, cognitive impairment, Guillain-Barré syndrome, encephalitis, migraine, seizures, movement disorders, mental illness, peripheral nerve disorders, veterans
MeSH terms
COVID-19, SARS-CoV-2, Brain Diseases, Humans, Male, Nervous System Diseases, Guillain-Barre Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review